Interstitial lung disease(ILD)is a heterogeneous disease characterized by diffuse pulmonary parenchyma,alveolar inflammation,and pulmonary fibrosis.At present,there are no ideal tools to diagnose and predict the prognosis of ILD.The application of biological markers can assist in the rapid diagnosis of the disease and guide clinical treatment decisions.Therefore,there is an urgent need for reliable,safety and feasible biomarkers to identify disease progression and treatment of interstitial lung disease,so as to achieve timely,accurate and personalized treatment for patients with interstitial lung disease.
维普
万方数据